![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Bajaj Healthcare Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from WHO-GMP.
One of their significant offerings is Chlorhexidine digluconate solution, supported by a 'Withdrawn by EDQM Failure to CEP procedure' Certificate of Suitability (CEP) with the number R0-CEP 2005-076 - Rev 01
This Chemical Type CEP, issued on December 20, 2010, remains in force until June 26, 2012, ensuring its reliability within the pharmaceutical industry.
Substance Number 658 associated with this CEP further emphasizes